215TiP - PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus stand...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Early Stage
Breast Cancer
Presenter Erica Mayer
Citation Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362
Authors E.L. Mayer1, A.M. Demichele2, G. Pfeiler3, W. Barry4, O. Metzger5, P. Rastogi6, F. Symmans7, H.J. Burstein4, K. Miller8, S. Loibl9, S. Schmatloch10, T. Goulioti11, D. Zardavas12, C. Fesl13, M. Koehler14, C. Huang Bartlett14, X. Huang15, M. Piccart16, E.P. Winer17, M. Gnant18
  • 1Dana-farber Cancer Institute, Breast Oncology Center, Harvard Medical School / Dana-Farber Cancer Institute, 02215 - Boston/US
  • 2Perelman Center For Advanced Medicine, University of Pennsylvania-Perelman Center for Advanced Medicine, 19104 - Philadelphia/US
  • 3Gyneology And Obstet, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 4Dana-farber Cancer Institute, Harvard Medical School / Dana-Farber Cancer Institute, Boston/US
  • 5Medical Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 6Division Of Hematology/oncology, Univ. of Pittsburgh Schools of the Health Sciences, Pittsburgh/US
  • 7Department Of Pathology, MD Anderson Cancer Center, Houston/US
  • 8Hematology/oncology, Indiana University School of Medicine, 46202 - Indianapolis/US
  • 9Medicine And Research, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE
  • 10Senology, Elisabeth Hospital, Kassel/DE
  • 11Medical Director, Breast International Group, Brussels/BE
  • 12Associate Medical Director, Breast International Group, Brussels/BE
  • 13Statistics, Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna/AT
  • 14Oncology, Pfizer, New York City/US
  • 15Oncology, Pfizer, San Diego/US
  • 16Chemotherapy Dept., Institute Jules Bordet, 1000 - Brussels/BE
  • 17Dana-farber Cancer Institute, Harvard Medical School / Dana-Farber Cancer Institute, 2215 - Boston/US
  • 18Department Of Surgery And Comprehensive Cancer Center  , Medical University of Vienna, 1090 - Vienna/AT

Abstract

Background

Cell cycle inhibition is a proven target for novel cancer therapeutics. Palbociclib (P) is an orally active inhibitor of CDK4/6, and arrests the cell cycle at the G1-S transition. P in combination with endocrine therapy (ET) has demonstrated efficacy in phase II and III randomized trials for patients with newly diagnosed and recurrent hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer (MBC), and is approved in these settings. Given confirmed benefits of P and ET for MBC, the PALLAS study was designed to determine if the addition of P to adjuvant ET improves outcomes over ET alone in HR+/HER2- early breast cancer.

Trial design

PALLAS is an international open-label phase III trial randomizing (1:1) patients (pts) to 2 years of P (125 mg daily, 21 days on 7 days off in a 28-day cycle) combined with at least 5 years of provider choice ET (AI, tamoxifen, +/- LHRH agonist), versus ET alone. The primary objective of the study is to compare invasive disease-free survival (iDFS) for the combination of P and ET, versus ET alone. Secondary objectives include comparison of iDFS excluding cancer of non-breast origin, DRFS, LRRFS, OS, as well as safety. The principal objective of the translational investigations is to determine the predictive or prognostic utility of defined genomic subgroups with respect to iDFS and OS. Additional objectives include evaluation of cfDNA and tissue biomarkers predictive of benefit or resistance, pharmacogenomics, adherence, and patient-reported QOL. Eligible pts are pre- or post-menopausal women or men with stage II-III, HR+/HER2- breast cancer. Patients may have already initiated ET, but must be randomized within 12 months of diagnosis and 6 months of initiation of adjuvant ET. Trial sample size is 4600 pts and stage IIA pts will be capped at a total accrual of 1000 pts. Interim analyses for safety, futility/efficacy and sample size re-estimation are planned. PALLAS opened in 9/2015 and accrual is ongoing. Contact information: emayer@partners.org.

Clinical trial identification

US: IND Nr.(FDA): 126003 clinicaltrials.gov NCT02513394 FDA approval 27 May 2015 Non-US (clinicaltrialsregister.eu dates): EudraCT Number: 2014-005181-30 Sponsor Protocol Number: AFT-05/ABCSG-42/BIG_14-03 Start Date: 2015-07-09

Legal entity responsible for the study

Alliance Foundation Trials (AFT) LLC for US, ABCSG GmbH for participating countries outside of the US

Funding

Pfizer

Disclosure

E.L. Mayer, H.J. Burstein, E. Winer: Research funding to the institution from Pfizer. A.M. Demichele: Funding to the institution for clinical trials from Pfizer, Novartis, Genentech and Calithera. Advisory board activities for Pfizer, Novartis and Calithera. M. Koehler, C. Huang Bartlett, X. Huang: Employee and shareholder of Pfizer. M. Gnant: Grants and/or personal fees from Sanofi-Aventis, Novartis, Roche, GlaxoSmithKline, AstraZeneca, Nanostring Technologies, Accelsiors, Pfizer, Smith Medical, outside the submitted work. All other authors have declared no conflicts of interest.